Evidence map›Paper›PMID 31030301›Full record

ArticleAIDS and behavior2020

Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.

Zoe Duby, Ariana W K Katz, Erica N Browne, Prisca Mutero, Juliane Etima, Chifundo Colleta Zimba, Kubashni Woeber, Millicent Atujuna, Krishnaveni Reddy, Ariane van der Straten and 1 more

Open access · greenAbstract read
In one paragraph

Article in AIDS and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Use of simulated vaginal and menstrual fluids to modelInternational journal of pharmaceutics: X · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Zoe DubyDivision of Social and Behavioural Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. zoe.duby@gmail.com.ORCID http://orcid.org/0000-0001-7615-8152
Ariana W K KatzWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Erica N BrowneWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Prisca MuteroUZCHS-CTU, Harare, Zimbabwe.
Juliane EtimaMakerere University - Johns Hopkins University, Research Collaboration, Kampala, Uganda.
Chifundo Colleta ZimbaUNC Lilongwe, Lilongwe, Malawi.
Kubashni WoeberSouth African Medical Research Council, Kwazulu Natal, South Africa.
Millicent AtujunaDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Krishnaveni ReddyWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Ariane van der StratenWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
MTN-020/ASPIRE Study Team
RTI International · USSouth African Medical Research Council · ZAUniversity of Cape Town · ZADesmond Tutu HIV Foundation · ZALilongwe University of Agriculture and Natural Resources · MWMUJHU Research Collaboration · UG

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
The Johns Hopkins University - Uganda Clinical Trials UnitUM1AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARY Glenn Fowler, Philippa Musoke · 2012 to 2026
$34.8M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
BIOMEDICAL INFORMATION DEVELOPMENT IN SUB-SAHARAN AFRICAD43TW001081 · FIC · JOHNS HOPKINS UNIVERSITY · PI TAHA, TAHA E · 1998 to 2003
$435k
FIC NIH HHS D43 TW001081Foundation for the National Institutes of Health UM1AI068633NIAID NIH HHS U01 AI069436NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069518NIAID NIH HHS UM1 AI069530NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

We assessed the interference between vaginal ring use and menses among women who participated in the qualitative component of the MTN-020/ASPIRE vaginal ring trial in Malawi, South Africa, Uganda and Zimbabwe (N = 214). A common reason for imperfect ring adherence and premature removal of the vaginal ring cited by participants related to vaginal bleeding or menses. Whereas self-reporting via survey questions suggested that the majority (60%) of women did not mind wearing the ring while menstruating, and did not remove it (91%) during menses, in the qualitative interviews women frequently described removing the ring during menses. Their reasons included hygiene, beliefs that the ring blocked the flow of menstrual blood, fears that the ring would come out with blood or during tampon removal, and concerns around an 'overburdened' vagina. Examining women's narratives and subjective experiences related to menstruation helps build a better understanding of factors affecting ring use and adherence.

Indexed as

Contraceptive Devices, FemaleHygieneMenstruationAdministration, IntravaginalAdultAnti-HIV AgentsFemaleHIV InfectionsHumansMalawiPatient CompliancePre-Exposure ProphylaxisQualitative ResearchSouth AfricaUgandaVaginal Creams, Foams, and JelliesAnti-HIV AgentsVaginal Creams, Foams, and JelliesAdherenceHIV preventionHygieneMensesMenstruationVaginal ring

Identifiers

PMID31030301
PMCPMC6815681
OpenAlexW2941560261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.